Davis J. E., EVP, General Diagnostics, subtracted 47,574 shares of Quest Diagnostics Incorporated (DGX) from its portfolio at the rate of $95.00 per share valuing $4,519,530 on Apr 24. The insider left behind 36,534 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Quest Diagnostics Incorporated (DGX) was $100.86. Currently, the 1st Resistance Point for this stock is $101.48, with a 2nd Resistance Point sitting at $102.09. Meanwhile, this company’s stock has a 1st Support Level at $99.72 and a 2nd Support Level at $98.57. Quest Diagnostics Incorporated (DGX) stock has gained $2.11, or 2.14%, in the past five days. In the last full month, these shares have gained $3.78, or 3.89%. In the past three months, this stock’s price has risen by $12.55, or 14.21%. This year-to-date, Quest Diagnostics Incorporated (DGX) shares have gained $17.59, or 21.12%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Quest Diagnostics Incorporated (DGX) stock, 100% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Buy .”
With 134,375 K shares outstanding, this company currently has a market capitalization of $13,370,312K. Quest Diagnostics Incorporated (DGX) generates $7,531 M in annual sales, amounting to annual net income of $736,000 K. This stock has generated a 1-Year Total Return of -8.86%, a 3-Year Total Return of 33.18%, and a 5-year Total Return of 70.72%. This stock’s 5-Year Dividend Growth is 62.50%, with its most recent dividend valued at $0.530 per share on 04/05/19. Its Annual Dividend Yield is 2.14%, and its Annual Dividend Rate is 2.12.
In the most recently-reported fiscal quarter, which ended in Mar-19, Quest Diagnostics Incorporated (DGX) reported earnings of $1.40 per share. Wall Street analysts, on average, were expecting the company to report earnings of $1.36 per share, representing a 0.04 difference and 2.71% surprise. In the previous quarter ending in Dec-18, the reported earnings of $1.36 represented a -0.01 difference from the consensus estimate calling for $1.37 per share, which was a 0.52% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is $1.70 per share. This estimate came from a total of 10 Wall Street Analysts. Of those market experts, the high estimate was $1.80 and the low estimate was $1.64. In the year-ago quarter, Quest Diagnostics Incorporated (DGX) generated per-share earnings of $1.75. If the analysts are correct about the current quarter’s earnings, the growth will be -2.86% .
Turning our focus now to insider trading activity, there have been 11 purchases (121,894 shares in total) and 5 sale (121,956 shares in total) in the last 3 months. In the last 6 months, there have been 28 insider buys amounting to 254,695 shares and 45 insider sales amounting to 210,369 shares. In the past full year, 32 insider purchases were made (involving 386,025 shares) and 55 insider sell-offs equivalent to 349,575 shares.
Moving onto liquidity, Quest Diagnostics Incorporated (DGX) has a Current Ratio of 0.94, a Quick Ratio of 0.87 and a Cash Ratio of 0.09. Looking at this company’s capital structure, its Total Debt to Total Equity is 76.51, its Total Debt to Total Capital is 43.35, and its Total Debt to Total Assets is now 36.27. Looking even further ahead into the future, its Long-Term Debt to Equity is 65.74 and its Long-Term Debt to Total Capital is 37.24.